SCHEMBL2710199

SCHEMBL2710199

COc1c(F)c(F)c(-c2c3ccccc3c(-c3c(F)c(F)c(F)c(F)c3F)c3c(F)cccc23)c(F)c1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TUBB4A P04350 5/20 0.33
TUBB P07437 5/20 0.33
TUBA3C P0DPH7 5/20 0.33
TUBA1B P68363 5/20 0.33
TUBA4A P68366 5/20 0.33
TUBB4B P68371 5/20 0.33
TUBB3 Q13509 5/20 0.33
TUBB2A Q13885 5/20 0.33
TUBB8 Q3ZCM7 5/20 0.33
TUBA3E Q6PEY2 5/20 0.33
TUBA1A Q71U36 5/20 0.33
TUBA1C Q9BQE3 5/20 0.33
TUBB6 Q9BUF5 5/20 0.33
TUBB2B Q9BVA1 5/20 0.33
TUBB1 Q9H4B7 5/20 0.33
CYP1A2 P05177 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12086107 1.00 KDM4E (0.38) KDM4EALDH1A1MAPK1SMN1; SMN2TUBB4A
SCHEMBL2709659 0.98 ALDH1A1 (0.39) KDM4EALDH1A1MAPK1SMN1; SMN2TUBB4A
SCHEMBL2712431 0.93 ALDH1A1 (0.35) KDM4EALDH1A1MAPK1SMN1; SMN2TUBB4A
SCHEMBL12086028 0.93 ALDH1A1 (0.35) KDM4EALDH1A1MAPK1SMN1; SMN2TUBB4A
SCHEMBL12086178 0.91 KDM4E (0.32) KDM4EALDH1A1MAPK1SMN1; SMN2TUBB4A
SCHEMBL2944207 0.91 KDM4E (0.32) KDM4EALDH1A1MAPK1SMN1; SMN2TUBB4A
SCHEMBL2727123 0.91 KDM4E (0.34) KDM4EALDH1A1MAPK1SMN1; SMN2TUBB4A
SCHEMBL2727156 0.91 KDM4E (0.34) KDM4EALDH1A1MAPK1SMN1; SMN2TUBB4A
SCHEMBL12086082 0.91 KDM4E (0.34) KDM4EALDH1A1MAPK1SMN1; SMN2TUBB4A
SCHEMBL2728240 0.91 KDM4E (0.34) KDM4EALDH1A1MAPK1SMN1; SMN2TUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2445987-B1 BLUE/VIOLET DIPHENYLANTHRACENE CHEMILUMINESCENT FLUORESCERS CYALUME TECH INC (US) 2018-05-02 EP disclosed
US-8257620-B2 Blue/violet diphenylanthracene chemiluminescent fluorescers CYALUME TECHNOLOGIES, INC. (US) 2012-09-04 US disclosed
EP-2445987-A1 BLUE/VIOLET DIPHENYLANTHRACENE CHEMILUMINESCENT FLUORESCERS Cyalume Technologies, Inc (US) 2012-05-02 EP disclosed
US-20100327240-A1 Blue/violet diphenylanthracene chemiluminescent fluorescers CYALUME TECHNOLOGIES, INC. 2010-12-30 US disclosed
WO-2010151654-A1 BLUE/VIOLET DIPHENYLANTHRACENE CHEMILUMINESCENT FLUORESCERS CYALUME TECHNOLOGIES, INC. (US) 2010-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100327240-A1 Blue/violet diphenylanthracene chemiluminescent fluorescers CYP2F1, FLAD1, AFF1 KDM4E 670/4885ALDH1A1 34/4885MAPK1 1977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.